Cimetidine 2% | Fluorouracil 5% | Salicylic Acid 20%
Cimetidine 2% | Fluorouracil 5% | Salicylic Acid 20% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
This triple-component compounded topical cream combines cimetidine 2% (H₂ receptor antagonist with immunomodulatory properties), fluorouracil 5% (antimetabolite chemotherapeutic agent), and salicylic acid 20% (keratolytic agent) for the prescriber-directed treatment of cutaneous warts and other hyperkeratotic viral lesions. Each ingredient contributes a distinct mechanism: salicylic acid physically softens and removes the hyperkeratotic wart tissue, fluorouracil inhibits DNA synthesis in actively dividing infected cells, and cimetidine modulates the local immune response against HPV-infected tissue. Genesis Compounding prepares this as a prescription-only 503A compounded preparation.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Cimetidine 2% | H₂ receptor antagonist that exerts immunomodulatory activity by enhancing T-cell-mediated immune responses against HPV-infected keratinocytes, potentially facilitating immune-directed wart clearance. |
| Fluorouracil 5% | Fluorinated pyrimidine antimetabolite that inhibits thymidylate synthase, blocking DNA and RNA synthesis in rapidly dividing HPV-infected cells, leading to their destruction. |
| Salicylic Acid 20% | Keratolytic agent that softens and dissolves the intercellular cement of keratinized cells, physically removing the dense hyperkeratotic wart surface and enhancing penetration of fluorouracil to the viable virus-containing tissue. |
Route: Topical application to wart lesions as directed by the prescriber.
- Apply to the wart surface (not surrounding normal skin) using the provided applicator.
- Before each application, soak the wart in warm water for 5 minutes and gently file the surface with an emery board or pumice stone to remove softened keratin.
- Cover with an adhesive bandage after application to maintain contact and prevent spread to surrounding skin.
- Wash hands thoroughly after application. Avoid contact with eyes, mucous membranes, and normal skin.
Dosing frequency and duration are prescriber-determined. General approach:
- Typically applied once or twice daily to wart lesions.
- Treatment duration varies; warts typically require weeks of consistent treatment. Prescriber will assess response and adjust frequency or duration as needed.
- High-concentration salicylic acid (20%) may cause skin irritation; if significant surrounding skin irritation develops, reduce frequency per prescriber guidance.
- Salicylic Acid (20%): Keratolytic mechanism: dissolves intercellular desmosomal connections in the stratum corneum, softening and physically degrading the hyperkeratotic wart surface; also acidifies the local environment, enhancing fluorouracil penetration and activity at the level of the living, virus-replicating cells.
- Fluorouracil (5%): Fluorinated pyrimidine antimetabolite; inhibits thymidylate synthase, blocking the methylation of deoxyuridine monophosphate (dUMP) to thymidine monophosphate (dTMP), thereby depleting thymidine for DNA synthesis; also incorporates into RNA, disrupting mRNA function; selectively targets rapidly dividing HPV-infected keratinocytes.
- Cimetidine (topical 2%): H₂ receptor antagonism at immune cell surfaces suppresses histamine-mediated immune downregulation; in cell-mediated immunity, cimetidine has been shown to block H₂ receptors on T-suppressor cells, enhancing net Th1 (cell-mediated) immune activity against HPV antigens; may also directly inhibit HPV-related cell proliferation.
This triple-combination wart cream is used prescriber-directed for recalcitrant or persistent cutaneous warts (common warts, plantar warts) that have failed or are refractory to standard therapies. The combination targets warts simultaneously via keratolysis, anti-proliferative cytotoxicity, and immune stimulation—complementary mechanisms that may produce additive efficacy.
Prescriber monitoring:
- Monitor surrounding skin for fluorouracil-related irritation (erythema, erosion, crusting); reduce frequency or interrupt treatment if significant toxicity occurs.
- Salicylic acid at 20% is a significant keratolytic; avoid excessive maceration of surrounding normal skin.
- Assess wart size and character at regular intervals to gauge response.
- Topical fluorouracil is teratogenic; women of childbearing potential should not use this preparation and must confirm they are not pregnant.
Contraindications:
- Pregnancy (topical fluorouracil is teratogenic)
- Application to face (especially periorbital areas), mucous membranes, or genitalia unless specifically directed
- Known hypersensitivity to fluorouracil, salicylic acid, cimetidine, or any formulation component
Warnings & Precautions:
- Fluorouracil teratogenicity: Topical fluorouracil can be absorbed systemically; avoid in pregnancy and in women of childbearing potential without confirmed contraception.
- Avoid application to large surface areas due to fluorouracil systemic absorption risk.
- Salicylic acid at high concentrations (20%) can cause significant local irritation and should not be applied to the face or intertriginous areas.
- Cimetidine may interact systemically if absorbed; at 2% topical concentration, systemic effects are unlikely but not impossible.
Drug Interactions:
- Cimetidine (systemic): inhibits CYP1A2, CYP2C9, CYP2D6, CYP3A4; potential interactions with many systemically administered drugs if significant topical absorption occurs—negligible at 2% topical concentration.
- Fluorouracil: warfarin levels may increase with systemic fluorouracil; topical absorption at 5% over small areas is minimal but consider in anticoagulated patients.
Common Side Effects: Local erythema, irritation, burning, crusting, and erosion at application site (fluorouracil, salicylic acid); surrounding skin maceration with high-concentration salicylic acid; temporary hyperpigmentation or hypopigmentation post-treatment.
Store at controlled room temperature (20–25°C / 68–77°F). Protect from heat and light. Keep tightly capped. Do not freeze. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children and away from pregnant individuals.
Why are three different ingredients used to treat warts?
Warts caused by HPV are notoriously difficult to treat. This combination simultaneously removes the tough outer wart surface (salicylic acid keratolysis), kills rapidly dividing infected cells (fluorouracil antimetabolite), and stimulates the immune system to target HPV-infected tissue (cimetidine immunomodulation)—a multi-pronged approach for persistent or recalcitrant warts.
How does salicylic acid help the fluorouracil work?
Salicylic acid physically breaks down the dense keratinized surface of the wart, which would otherwise act as a barrier preventing fluorouracil from reaching the virus-replicating cells underneath. By clearing this barrier, salicylic acid enhances fluorouracil penetration to where it can be most effective.
Is topical fluorouracil safe during pregnancy?
No. Fluorouracil is teratogenic. Women who are pregnant or may become pregnant must not use this preparation. This is a firm contraindication. Confirm non-pregnant status and use of effective contraception before prescribing.
Is this product FDA-approved?
Topical fluorouracil 5% is FDA-approved (Carac®, Efudex®) for actinic keratoses and basal cell carcinoma. This specific three-ingredient compounded combination is a 503A preparation from Genesis Compounding for patient-specific wart treatment, not an FDA-approved combination.
How long does treatment typically take?
Wart treatment requires weeks to months of consistent daily therapy. Prescribers typically reassess at 4–8 weeks. Do not discontinue early even if the wart appears to improve; the virus persists in basal keratinocytes and continued treatment is needed to prevent recurrence.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.